Literature DB >> 14641561

Temporal lobe epileptogenesis and epilepsy in the developing brain: bridging the gap between the laboratory and the clinic. Progression, but in what direction?

L Velísek1, S L Moshé.   

Abstract

The origins of human mesial temporal lobe epilepsy and hippocampal sclerosis are still not well understood. Hippocampal sclerosis and temporal lobe epileptogenesis involve a series of pathologies including hippocampal neuronal loss and gliosis, axonal reorganization, and maybe hippocampal neoneurogenesis. However, the causality of these events is unclear as well as their relation to the factors that may precipitate epileptogenesis. Significant differences between temporal lobe epileptogenesis in the adult and immature brain may require differential approaches. Hereditary factors also may participate in some cases of hippocampal sclerosis. The key point is to identify the significance of these age-dependent changes and to design preventive treatments. Novel strategies for the prevention and treatment of mesial temporal lobe epilepsy and hippocampal sclerosis may include rational use of neuroprotective agents, hormonotherapy, immunizations, and immunotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 14641561     DOI: 10.1111/j.0013-9580.2003.12008.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  Nitric oxide regulates activity-dependent neuroprotective protein (ADNP) in the dentate gyrus of the rodent model of kainic acid-induced seizure.

Authors:  Anna S Cosgrave; Jennifer S McKay; Richard Morris; John P Quinn; Thimmasettappa Thippeswamy
Journal:  J Mol Neurosci       Date:  2009-01-07       Impact factor: 3.444

2.  Interictal epileptiform discharges shape large-scale intercortical communication.

Authors:  Prawesh Dahal; Naureen Ghani; Adeen Flinker; Patricia Dugan; Daniel Friedman; Werner Doyle; Orrin Devinsky; Dion Khodagholy; Jennifer N Gelinas
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.